The integration of prediabetic management into routine cardiovascular care could be transformative, while there are controversial findings regarding the inconclusive impact of the agents, which are widely used in prediabetes/diabetes mellitus type II, i.e., Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, on the clinical course of STEMI [27]. This evidence concerns the gene SLC5A2 and prediabetes syndrome.